Avirmax, Inc. based in San Francisco Bay Area, is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and BAC-to-AAV technologies. Avirmax Adeno-associated Vector Innovation Platform (AAVIP), enables us to become a “powerhouse” of rAAV therapeutics for its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics at the most affordable and accessible manner. Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production based on its state of the art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.